TransMedics Group, Inc. cash flow to debt ratio of 41.06% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

TransMedics Group, Inc.'s free cash flow has increased -265.04% from $-80.94M last year to $133.59M, signaling increasing performance

TransMedics Group, Inc.'s debt to equity ratio is 1.75, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

TransMedics Group, Inc.'s debt has decreased relative to shareholder equity from 2.27 last year to 1.75 today, signaling strengthened financials

TransMedics Group, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

TransMedics Group, Inc.'s interest coverage ratio of 5.40 indicates that earnings with good margin can cover interest payments on company debt

TransMedics Group, Inc.'s profit margin has increased (236.62%) in the last year from 8.03% to 27.04%, signaling increasing performance

TransMedics Group, Inc.'s short-term assets of $637.78M exceed its short-term liabilities of $89.31M

TransMedics Group, Inc.'s return on assets of 11.98% is higher than the 5.00% threshold, indicating efficient asset utilization

TransMedics Group, Inc.'s return on equity of 41.92%, is higher than 15.00%, indicating good performance

TransMedics Group, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

TransMedics Group, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

TransMedics Group, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

TransMedics Group, Inc. has a free cash flow yield of 5.18%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

TransMedics Group, Inc.'s yearly earnings has increased 436.58% since last year from $35.46M to $190.29M, signaling increasing performance

TransMedics Group, Inc.'s yearly revenue has increased 37.13% since last year from $441.54M to $605.49M, signaling increasing performance

ROIC 6.94% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

TransMedics Group, Inc.'s 3-year revenue CAGR of 86.42% is positive, indicating growing revenue over the past 3 years

TransMedics Group, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

TransMedics Group, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

TransMedics Group, Inc. has insufficient data to evaluate this check.

TransMedics Group, Inc. has an earnings yield of 6.70%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

TransMedics Group, Inc. is overvalued relative to its fair value price of 30.85 based on EBITDA multiple model

TransMedics Group, Inc. has an EV/EBITDA ratio of 17.24x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

TransMedics Group, Inc. is overvalued relative to its fair value price of -34.37 based on Earnings Fair Value model

TransMedics Group, Inc. has a PEG-ratio under 1 which is considered undervalued

TransMedics Group, Inc. has a price-to-book ratio of 5.19x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

TransMedics Group, Inc. has a price-to-sales ratio of 4.03x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue